Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 18/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258536 | 0.92 | STING1 (0.69) | STING1LMNA | |
| SCHEMBL24258680 | 0.92 | STING1 (0.69) | STING1LMNA | |
| SCHEMBL20908471 | 0.92 | STING1 (0.65) | STING1 | |
| SCHEMBL20908440 | 0.92 | STING1 (0.72) | STING1LMNA | |
| SCHEMBL20908441 | 0.91 | STING1 (0.74) | STING1 | |
| SCHEMBL20908716 | 0.91 | STING1 (0.74) | STING1 | |
| SCHEMBL24354820 | 0.90 | STING1 (1.00) | STING1LMNA | |
| SCHEMBL23477313 | 0.90 | STING1 (1.00) | STING1LMNA | |
| SCHEMBL22216234 | 0.90 | STING1 (1.00) | STING1LMNA | |
| SCHEMBL116836 | 0.90 | STING1 (1.00) | STING1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2019074887-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | STING1 159/4885LMNA 2058/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | STING1 159/4885LMNA 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.